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Lymphoma is the most common haematopoietic malignancy in dogs, but little is known about the
aetiology of this heterogeneous group of cancers. In humans, the Epstein–Barr virus (EBV) is
associated with several lymphoma subtypes. Recently, it was suggested that EBV or an EBV-like
virus is circulating in dogs. We therefore investigated whether EBV, or a novel herpesvirus, is
associated with canine lymphoma using both serological and molecular techniques. In an assay
designed to detect antibodies to EBV viral capsid antigens, 41% of dogs were positive. Dogs
with cancers, including lymphoma, were more frequently positive than controls, but no particular
association with B-cell lymphoma was noted. EBV-specific RNA and DNA sequences were not
detected in lymphoma tissue by in situ hybridization or PCR, and herpesvirus genomes were not
detected using multiple degenerate PCR assays with the ability to detect novel herpesviruses. We
therefore found no evidence that herpesviruses are directly involved in common types of canine
lymphoma although cannot exclude the presence of an EBV-like virus in the canine population.
INTRODUCTION
Lymphoma is one of the most common malignancies
in dogs (Merlo et al., 2008) and despite treatment is
invariably fatal. Little is known about its aetiology and
pathogenesis, hampering efforts to develop new therapies.
Lymphomas in dogs and humans are a heterogeneous
group of tumours, and the spectrum of subtypes is similar;
in both species diffuse large B-cell lymphoma is the most
common form. Canine lymphoma has therefore been
proposed as a good model for the human disease (Vail &
MacEwen, 2000) and parallels between lymphoma in the
two species suggest that findings in human non-Hodgkin
lymphoma will be relevant to the canine disease. Epstein–
Barr virus (EBV) causes a significant minority of human
lymphomas, which are mainly of B-cell origin (Young &
Rickinson, 2004). Several recent publications suggest that
EBV or an EBV-like virus is circulating in dogs (Chiou
et al., 2005; Chiu et al., 2013; Huang et al., 2012; Milman
et al., 2011) and it is therefore possible that this virus also
causes some canine B-cell lymphomas. Identification of an
EBV-like virus in canine lymphomas would not only aid
classification of these tumours, but would help elucidate
the underlying mechanisms of oncogenesis.
EBV (Human herpesvirus 4; HHV-4) belongs to the family
Herpesviridae, subfamily Gammaherpesvirinae; members
of this subfamily exhibit lymphotropism and are more
commonly associated with cancer than other members of
the family Herpesviridae (Damania, 2004). EBV infection in
humans is ubiquitous and generally asymptomatic (Henle
et al., 1969). The virus infects epithelial cells and B-cells,
and following primary infection establishes a reservoir of
infection within the resting memory B-cell pool (Babcock
et al., 1998). It is causally associated with a range of
lymphoid and epithelial cell tumours, including Hodgkin
lymphoma, Burkitt lymphoma, post-transplant lympho-
proliferative disease, nasal T/NK-cell lymphoma, and naso-
pharyngeal and gastric carcinoma (Young & Rickinson,
2004). Although EBV encodes a large number of proteins,
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transformation is associated with expression of a restricted
group of non-structural proteins and RNAs that drive
tumour proliferation. These include six EBVnuclear antigens
(EBNA1, 2, 3a, 3b, 3c and LP), two latentmembrane proteins
(LMP1 and 2) and the EBV-encoded RNAs (EBERs).
Although not all of these proteins are expressed in all
tumours, the EBERs are expressed in all cells latently infected
with EBV and all EBV-associated tumours (Rezk & Weiss,
2007). A second human gammaherpesvirus, HHV-8, is
causatively associated with Kaposi’s sarcoma (an endothelial
tumour) and also rare types of lymphoma, including primary
effusion lymphoma (Carbone & Gloghini, 2008). Herpes-
viruses are generally host-specific, having co-evolved with
their native species, and although cross-species transmission
is rare, it is often associated with high morbidity and
mortality (Tischer & Osterrieder, 2010).
Recent results from both serological and molecular studies
suggest that a gammaherpesvirus is circulating in dogs.
Using Western blot assays designed to detect antibodies to
EBV viral capsid antigens (VCA), Chiou et al. (2005) repor-
ted positive results in serum from 32 of 36 healthy domestic
dogs in Taiwan. Using a PCR assay based on the EBV BamHI
W sequence, EBV-specific sequences were detected in 15 of
21 canine blood samples and, in a later study, in 10 of 12
samples from a diverse range of oro-nasal tumours (Chiu
et al., 2013). These results suggested that EBVmay have been
transmitted from human to dog. Milman et al. (2011) used
an indirect immunofluorescence assay (IFA) to screen
serum samples from healthy domestic dogs in the UK and
USA for antibodies to EBV VCA, with 43 of 112 and 67 of
104 scoring positive, respectively. Infection of dogs by EBV
was not supported by molecular data, with only one of 104
palatine tonsil samples testing positive in an EBV-specific
BamHI W PCR assay. A further 50 blood and 33 lymphoma
tissue samples were negative. Additional screening was
performed with a degenerate PCR assay designed to detect
regions of the polymerase gene conserved across multiple
herpesviruses, but detected only Canid herpesvirus 1 (CHV-
1), subfamily Alphaherpesvirinae, in 13 of 137 samples.
Huang et al. (2012) investigated the potential role of EBV,
or an EBV-like virus, in canine lymphoma. Using recombi-
nant VCA proteins in an ELISA, they detected reactivity in
serum from healthy dogs and dogs with lymphoma, and
reported that dogs with B-cell lymphoma had higher anti-
body titres to EBV VCA than those with T-cell lymphoma.
Using a degenerate herpesvirus polymerase gene PCR assay,
positive results were obtained in two of three B-cell
lymphoma samples. Subsequently, EBV EBNA3C-specific
sequences were detected in samples from three of nine B-
cell lymphomas. In contrast to the initial studies by Chiou
et al. (2005), sequencing of products from the degenerate
PCR suggested that an EBV-related virus, rather than EBV
itself, was present in the canine samples.
Degenerate PCR techniques use areas of conserved amino
acid sequence within a protein family to detect unknown
family members. Assays based on conserved motifs in the
herpesvirus polymerase and glycoprotein B (gB) proteins
have been used successfully to identify many novel
herpesviruses, including gammaherpesviruses, in a diverse
range of species, including those of the orders Primates,
Artiodactyla and Carnivora (Ehlers et al., 2008). Analysis
of these sequences led to the formation of a new genus,
Percavirus, within the subfamily Gammaherpesvirinae. This
genus brings together viruses from several carnivores,
including cat and hyena, and it is likely that novel canine
gammaherpesviruses would belong to this group.
The aimof this studywas to determinewhether a herpesvirus,
particularly a gammaherpesvirus, is involved in the patho-
genesis of canine lymphoma by using both serological and
molecular techniques, including degenerate PCR assays, to
investigate common types of canine lymphoma.
RESULTS
Serological reactivity detected in EBV VCA assays
Serum or plasma samples from 234 dogs were screened
using an IFA designed to detect antibodies to EBV VCA
(Henle et al., 1969; Milman et al., 2011). In total, 97
samples (41%) scored positive. Positive canine samples
displayed cytoplasmic fluorescence in a proportion of cells,
comparable with that seen with human positive controls
(Fig. 1). Twenty samples, including 10 that were positive
and 10 that were negative by EBV VCA IFA, were tested in
a CHV-1 neutralization assay, but none was positive,
indicating that positivity did not result from cross-
reactivity with CHV-1. This is consistent with the findings
of Milman et al. (2011). In the combined cancer group, 90
of 195 (46%) scored positive compared with seven of 39
(18%) in the control group and differences were
statistically significant (x2 test, P50.001). The proportion
of dogs with lymphoma that scored positive (70 of 158;
44%) was lower than that of dogs with other cancers (20 of
37; 54%), but this difference was not statistically significant
(x2 test, P50.28). Amongst lymphoma cases with available
data (n5115), positivity did not vary significantly by B- or T-
cell immunophenotype, sex or age. Antibody titres were
similar indogswithB- andT-cell lymphoma(geometricmean
titre 34.09 and 29.97, respectively).
(a) (b)
50 µm 50 µm
Fig. 1. EBV VCA immunofluorescence using canine sera. (a)
Negative serum demonstrating dull green background staining. (b)
Positive serum with individual fluorescing cells against a duller
background.
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To investigate whether positivity in the IFA assay was
specific for EBV VCA, 12 samples were tested for
reactivity with a recombinant EBV VCA p18 protein
(VCA-rp18) by Western blot analysis. Using IFA-positive
human sera as positive controls, a band was observed just
below the 38 kDa size marker; this corresponded to the
expected size of the glutathione S-transferase (GST)-
tagged protein (Fig. 2a). No reactivity was detected using
the human negative control, but a band of the same size
was visible in all canine samples, both IFA-positive and -
negative. In both groups, these bands varied in intensity,
although with one exception IFA-negative samples gave
fainter bands. To further test the specificity of the
antibody binding, two samples from each group and a
human positive control were pre-incubated with VCA-
rp18, a non-related GST-tagged viral protein [feline
immunodeficiency virus (FIV) p24], concentrated BSA
or dilution buffer prior to Western blot analysis. A
reduction in band intensity was seen with all samples in
the group pre-incubated with VCA-rp18, but not with
samples in other groups (Fig. 2b).
Quantitative PCR (qPCR) does not detect EBV
genomes in canine tissue samples
A qPCR assay to the BamHI W repeat region of EBV was
used to screen 111 canine samples, comprising 62 B-cell, 39
T-cell and one null-cell lymphoma, and nine samples from
reactive lymphoid or other tumour tissue. The assay was
highly sensitive, consistently detecting two copies of EBV in
the human cell line Namalwa, which contained one EBV
genome per cell. All canine samples were negative.
In situ hybridization (ISH) does not detect EBER
RNAs in canine lymphomas
ISH for EBERs was employed to identify canine tissues
containing cells latently infected by EBV. Sections from
seven B-cell, two T-cell and one null-cell lymphoma were
tested. Clear nuclear staining was seen within tumour cells,
but not bystander cells in sections from the EBV-associated
Hodgkin lymphoma sample, which was used as the positive
control. All canine samples were scored negative.
No evidence of herpesvirus sequences in canine
tissue samples by degenerate or ‘canine-specific’
PCR
Samples from 112 canine samples were tested by semi-nested
PCRusing a degeneratePCRbased on conserved sequences in
the herpesvirus polymerase protein (‘POL assay’). Samples
were from 68 B-cell, 33 T-cell and one null-cell lymphoma,
three ‘other tumours’, and seven reactive lymphoid tissues;
serum samples from nine patients were positive by EBVVCA
IFA and 16 were negative. Analysis of dilutions of control
1 2 3 4
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Canine IFA-positive
1A 1B 1C 1D 7A 7B 7C 7D 9A 9B 9C 9D 12A12B12C12D +A +B+C +D
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Fig. 2. Reactivity with recombinant EBV VCA p18-GST protein in selected canine plasma samples. (a) Canine plasma samples
were screened for antibodies to VCA-rp18 by Western blotting. Samples included seven which had tested positive by EBV
VCA IFA, five negative by IFA and three human samples, two positive by IFA and one negative. A major band migrating just
below the 38 kDa size marker is seen in all samples with the exception of the human negative control. (b) Canine samples 1, 7,
9 and 12, marked with an asterisk in (a), were used in subsequent blocking experiments. These samples, comprising two
positive by IFA and two negative, and a human positive sample were pre-incubated with VCA-rp18 (A), FIV p24-GST (B), 10%
BSA (C) or dilution buffer (D) prior to Western blotting. In all samples, there is a reduction in the intensity of the major band in
strip A (VCA-rp18) in comparison with the other three strips.
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DNA samples demonstrated that this assay could consistently
detect 250 copies of EBV, 500 copies of HHV-6B and 5000
copies of human cytomegalovirus (HCMV; HHV-5).
Positive controls were positive in all assays and all water
controls were negative. The expected amplicon size for
known herpesviruses ranges from 238 (EBV, Fig. 3a; HHV-
6B, Fig. 3b) to 313 bp (HCMV, Fig. 3c). The 59 and 39primers
were labelledwith different fluorochromes; therefore, specific
products would be labelled with both dyes. Most canine
samples yielded products outside the expected size range that
were labelled with only a single fluorochrome (Fig. 3d); this
indicated that these were non-specific products – an inherent
feature of assays incorporating highly degenerate primers.
Seven B-cell lymphoma, two T-cell lymphoma and two
reactive tissue samples yielded dual-labelled products.
Most were outside the expected size range for herpesvirus
amplicons, most commonly ~200 (Fig. 3d) or 325 bp.
Products from six samples, ranging in size from 170 to
325 bp and including two samples within the expected size
range for herpesviruses, were successfully cloned, sequenced
and subjected to BLAST and BLAT searches. No matches to
herpesvirus sequence were detected. Five amplicons had
99–100% identity to repeat regions of the canine genome;
the final 200 bp amplicon had ~70% identity, over 50–70%
of its length, to eukaryotic DNA polymerases from a diverse
range of species, including Canis familiaris.
Alignment of amino acid sequences from the polymerase
protein of the recently described genus Percavirus demon-
strated a mismatch in the pentapeptide sequence (YPSII/M
to YPTII) used to design the outer 59 primer of this assay.
As the inner 59 sequence, based on YGF/VTG, is perfectly
conserved amongst gammaherpesviruses, a subset of
samples was tested with the inner primer set only
(gammaherpesvirus POL assay). These samples comprised
24 B-cell lymphomas, 13 T-cell lymphomas, one null-cell
lymphoma and two samples from reactive lymphoid tissue.
This single-round assay consistently detected 250 copies of
EBV, but no dual-labelled products of the expected size
were detected in any of the samples. All water controls were
negative. Products of 200 and 310 bp were noted in almost
all of the 40 canine samples (Fig. 3e). A 200 and a 310 bp
product from a single case, along with a 200 bp product
(a)
Size (bp) 300250200150100 350
Size (bp) 300250200150100 350 300250200150100 350 244 299 421 539 674
300250200150100 350 300250200150100 350
(d) (e) (f)
(b) (c)
Fig. 3. Representative electropherograms from degenerate herpesvirus PCR. Open arrows indicate the described products.
Size markers are shown in red with size (bp) indicated below. (a) Semi-nested POL assay. EBV control (250 copies) yields
product of 238 bp dual-labelled in blue and green. (b) Semi-nested POL assay. HHV-6B control (iciHHV-6B DNA; 500 copies)
yields product of 238 bp dual-labelled in blue and green. (c) Semi-nested POL assay. HCMV control (clinical isolate; 5000
copies) yields product of 313 bp dual-labelled in blue and green. The product.350 bp labelled in blue only is non-specific. (d)
Semi-nested POL assay. Canine sample yields product of 200 bp dual-labelled in blue and green; sequencing revealed canine
genomic sequence. Products .350 bp labelled in blue only are non-specific. (e) Gammaherpesvirus POL assay. Canine
sample yields products dual-labelled in blue and green at ~200 and 310 bp; sequencing revealed canine genomic sequence.
(f) gB assay. HHV-8 control (150 copies) yields product of ~500 bp labelled in blue and green.
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from a separate case were successfully cloned and
sequenced. The 200 bp products had identical sequence,
which BLAT searches revealed had 100% identity to an
undefined region of canine chromosome X. The 310 bp
product had 100% identity to a portion of the CCDC57
gene on canine chromosome 9.
The same subset of 40 samples was tested using a
degenerate PCR assay based on the gB gene of gamma-
herpesviruses. This assay consistently detected 150 copies
of the HHV-8 genome (Fig. 3f), but no dual-labelled
products of the expected size were found in the canine
samples. Numerous products outside the expected size
range were amplified from all canine samples. All water
controls were negative.
Huang et al. (2012) described a short length of nucleotide
sequence, suspected to be a novel canine gammaherpes-
virus polymerase gene sequence. Twenty canine B-cell
lymphoma samples were tested using primers specific to
this sequence. Five samples were from patients who were
positive by EBV VCA IFA and seven were from IFA-
negative patients. The assay was initially run using 250 ng
tumour DNA as template, but no amplification products
were detected in either canine samples or Namalwa DNA,
used as a positive control (Fig. 4a). The assay was repeated
using 2 ml first-round product from the degenerate POL
assay as template. No product of the correct size was seen
in any of the canine samples, but a clear product of
~200 bp was detected in the positive control (Fig. 4b). This
fragment was cloned and sequenced, and corresponded to
part of the polymerase gene of EBV. It had been amplified
with the 59 primer from the assay and the 39 primer from
the original degenerate POL assay, which had presumably
been carried over from the outer PCR. The putative
canine-specific 39 primer sequence was not present in the
amplicon.
DISCUSSION
In this study, we used serological and molecular techniques
to investigate whether a novel canine herpesvirus is directly
involved in the pathogenesis of canine lymphoma. The
serological data presented here are consistent with the idea
that dogs in the UK have been exposed to EBV or a related
virus. Over a third of serum samples tested in an EBV IFA –
the gold standard for detecting EBV seropositivity in humans
– scored positive. The IFA employed in this study used an
infected human cell line as the antigen source, raising the
possibility that the reactivity resulted from cross-reaction
with a protein other than EBV VCA. To confirm assay
specificity, sampleswere analysed byWestern blot assay using
a recombinant EBV protein (VCA-rp18). In this assay,
samples both positive and negative by EBV VCA IFA
displayed reactivity, suggesting either greater sensitivity or
non-specific binding in the Western blot assay. To address
this, antibody was adsorbed by pre-incubation of sera with
VCA-rp18. This resulted in a clear and consistent, albeit
incomplete, reduction in band intensity; in contrast, no
reductionwas seenwhen sera were pre-incubatedwith a non-
related viral protein or a non-specific protein, suggesting at
least partial specificity for EBV VCA.
If an EBV-like herpesvirus is involved in the development
of canine B-cell lymphoma, then dogs with virus-associated
lymphomas would be expected to have higher antibody
titres, or a higher prevalence of viral antibodies, than
dogs with other conditions. Dogs with cancers, including
lymphoma, were more likely to score positive in the IFA
than healthy dogs; however, no differences in seropositivity
were noted between dogs with lymphoma and those with
other cancers, and antibody titres and seroprevalence were
similar in dogs with B- and T-cell lymphoma. We therefore
did not find any evidence to support a specific association
with B-cell lymphoma, although we cannot rule out an
association between seropositivity and a subgroup of B-cell
lymphomas. Our results could be explained by viral
reactivation in sick dogs.
The serology results are broadly in agreement with previously
published work, although we detected a lower prevalence of
anti-EBV VCA antibodies in our control series than the most
comparable study (Milman et al., 2011). Analysis of a larger
number of control samples is required to resolve this
difference, which may relate to assay sensitivity. Our data




(b) MNam S20 S19 S18 S18 S19 S20 NamH2O H2O H2O H2O
Fig. 4. Analysis of canine samples using a gammaherpesvirus-specific PCR assay. Representative gel images. Positions of 100
and 200 bp markers are indicated; the specific product in this assay would be expected to be ~150 bp. M, marker; Nam,
positive control (Namalwa); S18-20, canine samples. (a) Tumour DNA as template. No products are detected in sample, water
or positive control lanes. (b) PCR products of semi-nested POL assay as template. A band of ~200 bp (arrow) is seen in the
positive control lane. Sequencing confirmed that this was derived from EBV. No bands of this size are seen in sample or water
lanes.
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(2012) who reported that dogs with B-cell lymphoma had
higher anti-EBV VCA antibody titres than those with T-cell
lymphoma or controls in ELISAs. Differences could relate to
assay sensitivity or sampling error as numbers were relatively
small in both studies.
Taken together, these data suggest that EBV or a closely
related virus may be circulating in dogs. This prompted
us to perform molecular studies to try and identify the
potential agent; as our primary aim was to investigate the
aetiology of canine lymphoma, we examined tissue samples
with a focus on B-cell lymphoma. We favoured the idea
that an EBV-like virus, rather than EBV itself, may be
involved as herpesviruses are highly species-specific and
rarely cross species barriers (Tischer & Osterrieder, 2010).
However, to rule out infection with EBV, we initially
screened samples using an EBV-specific qPCR assay based
on the EBV BamHI W fragment. This assay detects a repeat
region in the viral genome and thus is extremely sensitive,
consistently detecting two viral copies per reaction. Analysis
of 111 samples revealed no positive results. We also tested for
EBV using EBER ISH – the gold standard for determination
of EBV positivity within human tumour tissue (Gulley &
Tang, 2008). A characteristic pattern of nuclear staining is
seen using this assay and it is important to distinguish true-
positive staining from non-specific staining, particularly of
eosinophils and plasma cells, which is sometimes observed.
Nopositive stainingwas seen in any of our samples. Although
the sample size was small, numbers were similar to other
studies. Together, these results make it highly unlikely that
EBV is present in, or is involved in, canine lymphoma, despite
previous reports that EBV sequences and positive EBER
staining are present in canine samples (Chiou et al., 2005;
Chiu et al., 2013; Huang et al., 2012).
To determine if another herpesvirus is present in canine
tissue samples, multiple degenerate PCR strategies were
employed. Such assays are based on amino acid regions
that are well-conserved amongst family members and allow
the detection of hitherto unknown viruses. Particular effort
was made to ensure the assays would detect percaviruses,
which include gammaherpesviruses of other carnivores,
as it is likely that a novel canine gammaherpesvirus would
belong to this group. Similar assays have been used suc-
cessfully to identify multiple novel gammaherpesviruses,
including three recently discovered feline gammaherpes-
viruses (Ehlers et al., 2008; Troyer et al., 2014).No evidence of
herpesvirus infection was found in 112 canine tissue samples
using the semi-nested POL assay – the most sensitive of
the three assays used. Negative results were also obtained
following analysis of a subset of 40 samples using assays
targeting sequences conserved in gammaherpesviruses.
Sequencing of products in the expected size range of herpes-
virus amplicons further confirmed that no herpesvirus
sequence was present.
Although degenerate PCRs are less sensitive than standard
PCRs, testing of the assays indicated that they had high
sensitivity for the control herpesviruses EBV, HHV-6B,
HCMV and HHV-8. This level of sensitivity is sufficient to
detect viruses present in virally associated tumours, which
would be expected to have at least one viral genome per
cell. Capillary electrophoresis was used to visualize prod-
ucts as it increases assay sensitivity and, in combination
with fluorescent labelling of primers, helps to exclude non-
specific amplification, an intrinsic feature of assays using
degenerate primers. Stringent measures were observed
throughout to avoid PCR contamination and false-positive
results.
These results contrast with other studies, where two of
three dogs with B-cell lymphoma and 10 of 12 dogs with
oral tumours were PCR-positive (Chiu et al., 2013; Huang
et al., 2012). This is the largest group of canine lymphoma
tissue samples tested to date and thus, by comparison, we
expected some positive cases. Huang et al. (2012) utilized a
similar degenerate polymerase gene PCR to this study,
amplifying a product from one canine B-cell lymphoma.
They subsequently designed a ‘canine-specific’ primer based
on the sequence of this product which was used to identify an
additional positive sample. We tested a larger case series with
the latter assay, but amplified no products from canine B-cell
lymphoma samples. Whilst the PCR data conflict with
previously published work, we are confident that we would
have detected a virus present in the tumour cells given the
number of samples that were analysed and the sensitivity of
the assays.
In conclusion, our results provide no evidence that a canine
gammaherpesvirus is involved in common subtypes of
canine lymphoma. We cannot exclude the possibility that a
gammaherpesvirus is involved in rare lymphoma subtypes
not included in the current study, analogous to HHV-8
involvement in primary effusion lymphoma. Whilst we did
not identify viral sequences in our canine lymphoma samples,
it is possible that a canine gammaherpesvirus is circulating in
dogs and is present at a low level in lymphoid cells in healthy
dogs. Further investigations are required to resolve this issue
and determine whether the serological findings reported here
and in other studies do indeed reflect infection with an EBV-
related virus.
METHODS
Patients and samples. Clinical samples were obtained from
untreated patients presenting to the Oncology service at the University
of Glasgow Small AnimalHospital, UK or the Centro Veterinario Berna,
Portugal. Samples consisted of excess material taken as part of routine
evaluations at the time of diagnosis. Ethical approval for their use was
obtained from the Faculty of Veterinary Medicine Ethics and Welfare
Committee, University of Glasgow. Diagnoses were confirmed by
cytology or histopathology. Lymphoma lineage was established by PCR
for antigen receptor rearrangements and,where possible, flow cytometry
or immunohistochemistry.
Serum or plasma was collected from 195 cases with lymphoma or
other tumour types, and 39 healthy controls undergoing routine
haematology and biochemistry evaluations prior to use as blood
donors (Table 1). All serum and plasma samples were collected from
dogs in the UK. The case series included a wide range of breeds;
E. M. Waugh and others
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crossbreed and Labrador were the most common, although the
proportion of these breeds was similar amongst dogs with lymphoma
and dogs with other tumour types. Sex, age and breed information
was not available for controls, but all were in the age range 1–8 years
and weighed .25 kg. Serum or plasma was separated within 24 h of
collection and stored at 280 uC until use.
Tissue samples were collected from 125 patients and included fresh
material from fine needle aspirates or biopsies (n5112), or formalin-
fixed, paraffin-embedded (FFPE) material from biopsies (n513)
(Table 2). Samples were collected from dogs in the UK (n554) and
Portugal (n571). Most were from lymph nodes; all samples contained
a high proportion of lymphoid cells and had a differential diagnosis of
lymphoma. A wide range of breeds was represented, with none
predominating except for Boxer in the T-cell lymphoma group (nine
of 40). Information on neutering status was not available for the
Portuguese samples. In the majority of cases, fresh samples were
processed within 24 h of collection. DNA was extracted from tissue
samples using standard methods and stored at 280 uC until use.
EBV VCA IFA. EBV VCA IFA was performed using P3HR1 cells as
described previously (Milman et al., 2011), with minor modifications.
To investigate whether this assay detected reactivity with CHV-1,
20 serum samples, including 10 that were positive and 10 that
were negative by EBV VCA IFA, were screened for CHV-1 by virus
neutralization (Veterinary Diagnostic Services, University of Glasgow).
Canine sera were diluted 1 : 10 for initial screening and a 1 : 100 dilution
of FITC-conjugated sheep anti-dog IgG (AbD Serotec) was used as
the secondary antibody. Human sera diluted 1 : 10 were used as positive
and negative controls alongside appropriate control canine sera
once identified. Slides were scored independently by two individuals.
Where canine sera tested positive, the antibody titre was determined
by analysing a twofold dilution series to 1 : 320. The proportion of
positive samples in groups was compared and statistical significance
determined using x2 analysis implemented in SPSS version 19 (IBM). In
the lymphoma group, the effect of immunophenotype, sex and age
was assessed using binary logistic regression. Geometric mean titres
of samples from dogs with B- and T-cell lymphoma (n513 and 12,
respectively) were compared, and statistical significance of differences
in log titre was determined using a two-sample t-test.
Western blot analysis. Western blot analysis was performed on 12
canine sera: seven positive and five negative by EBV VCA IFA.
Recombinant EBV VCA p18 protein tagged with GST (VCA-rp18;
Dundee Cell Products) was resolved on a 12% polyacrylamide gel and
transferred to nitrocellulose membrane. The membrane was cut into
strips: each strip contained ~800 ng VCA-rp18. Each strip was
incubated with serum or plasma diluted 1 : 20 for 1 h. After washing,
the strips were incubated with a 1 : 1000 dilution of biotinylated
Protein A (Calbiochem) for 30 min. Reactivity was detected using
Vectastain ABC-Amp and BCIP/NBT Substrate kits (Vector) according
to the manufacturer’s instructions. Human plasma samples, diluted
1 : 20, that were positive and negative by EBV VCA IFA were used as
positive and negative controls, respectively.
Blocking experiments were carried out on four samples: two positive
and two negative by EBV VCA IFA. Sera diluted 1 : 20 were pre-
incubated with 2 mg VCA-rp18, 5 mg FIV p24-GST (a kind gift from
Professor Brian Willett, University of Glasgow) or 10% BSA for 2 h at
room temperature. Western blot analysis was carried out as above.
EBV BamHI W qPCR. qPCR was performed using TaqMan
methodology (Applied Biosystems) and primers amplifying the
BamHI W repeat region of EBV as described previously (Gallagher
et al., 2003) (Table 3). DNA (250 ng) from 98 fresh and 13 FFPE
tissue samples was assayed using 16 TaqMan Universal Master Mix
without UNG (Applied Biosystems). Tenfold dilutions of DNA from
the EBV-positive Namalwa cell line (150 000 to 1.5 copies) were used
as a positive control, with water as a negative control after every two
samples. Amplification using default parameters for 40 cycles and
analysis were performed on a 7500 Real-Time PCR System with
Sequence Detection Software version 2.0.6 (Applied Biosystems).
EBER ISH. FFPE tissue sections from 10 UK lymphoma patients were
tested for the presence of EBV EBER RNAs as described (Jarrett et al.,
2013), using an EBV EBER PNA (peptide nucleic acid)-FITC probe
and a PNA ISH Detection kit (both Dako). Samples comprised seven
B-cell, two T-cell and one null-cell lymphoma; nine were from lymph
node and one was from a gastric mass. The positive control was from
a human EBV-associated Hodgkin lymphoma sample.
Degenerate PCR assays. Three different degenerate PCR strategies
for identification of novel herpesviruses were used; two of these were
based on conserved regions of mammalian herpesvirus polymerase
proteins and the third was based on motifs in the gB protein present
in many gammaherpesviruses (Ehlers et al., 2008; Gallagher et al., 2002;
Jarrett et al., 2013). The primary POL assay was run in a semi-nested
Table 1. Characteristics of patients included in serological analysis
All samples were collected in the UK.
Diagnosis Type* N Sex (F : FN :M :MN)D Age (years :months)
Median Range
Lymphoma B-cell 62 8 : 18 : 21 : 15 7 : 0 8 : 0–13 : 8
T-cell 48 5 : 13 : 16 : 14 7 : 3 1 : 5–12 : 3
Mixed 1 0 : 1: 0 : 0 7 : 11 7 : 11
Null-cell 3 0 : 3: 0 : 0 6 : 7 6 : 6–8 : 4
NOS 44 7 : 9: 18 : 10 7 : 7 1 : 7–16 : 7
Other cancer Other 37 2 : 17 : 6 :12 8 : 0 3 : 9–13 : 9
Control Healthy 39 Unknownd Unknownd 1 : 0–8 : 0d
*NOS, not otherwise specified; patients with ‘Other’ cancers comprised: mast cell tumour (n512), sarcoma (n58), osteosarcoma (n56), carcinoma
(n55), haemangiosarcoma (n52), and histiocytic tumour, melanoma, neuroectodermal bone tumour and thymoma (n51 each).
DF, female; FN, female neutered; M, male; MN, male neutered.
dThe sex and exact age of these patients was not known, although all were aged between 1 and 8 years.
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format, as describedpreviously (Jarrett et al., 2013). Theouter 59primers
(POL1A and B) were based on the pentapeptide sequence YPSII/M
and the inner 59 primers were based on YGF/VTG (POL3A and B);
both outer and inner reactions used a 39 primer (POL2B) based on
the pentapeptide YGDTD. The 59 primers in both outer and inner
primer sets were split into two syntheses to limit degeneracy and
increase sensitivity. Each primer also contained a 59 non-degenerate
clampbased on the consensus nucleotide sequence immediately 59 to the
degenerate primer. As it is now apparent that the YPSII/M sequence is
not perfectly conserved in all mammalian herpesviruses, particularly
gammaherpesviruses, a subset of samples was analysed using only the
inner primer set POL3B and POL2B (gammaherpesvirus POL assay).
These primers are based on amino acid sequences that are perfectly
conserved amongst all gammaherpesvirus protein sequences currently
available. The third PCR strategy utilized gB primers that were described
previously by Ehlers et al. (2008) and used to successfully amplify novel
feline gammaherpesviruses (Troyer et al., 2014). The complete series of
112 DNA samples was analysed using the semi-nested POL assay (Table
2), and a subset of 40 samples was analysed using the gammaherpesvirus
POL and gB assays.
All PCRs contained 250 ng DNA extracted from fresh tissue or cells,
16 HotStarTaq Plus Master Mix and 16 Q-Solution (Qiagen).
Primers (Table 3), labelled with HEX (59 primers) or 6-FAM
Table 2. Characteristics of patients included in molecular analysis
Diagnosis N Source Sample type Site* Sex (F : FN :M :MN)D Age (years :months)
Median Range
B-cell lymphoma 27 UK Fresh LN (18); B (5); AF (1);
BM (1); MM (1); SP (1)
2 : 12 : 6 : 7 7 : 6 3 : 0–14 : 0
41 Portugal Fresh LN 20 : 21 10 : 0 4 : 0–17 : 0
6 Portugal FFPE LN 4 : 2 10 : 6 9 : 0–12 : 0
T-cell lymphoma 19 UK Fresh LN (9); B (5); BM (1); AH
(1)
2 : 9 : 1 : 6 7 : 11 4 : 0–12 : 3
14 Portugal Fresh LN 6 : 7 10 : 0 3 : 0–15 : 0
7 Portugal FFPE LN 3 : 4 11 : 0 4 : 0–15 : 0
Null-cell lymphoma 1 UK Fresh LN 0 : 1: 0 : 0 6 : 8 6 : 8
Other 7d UK Fresh LN (3); BM (1); MM (1);
SP (1); TM (1)
0 : 2: 0 : 4 8 : 0 1 : 7–9 : 4
3§ Portugal Fresh LN 0 : 2 7 : 0 5 : 0–9 : 0
*LN, lymph node; B, blood; AF, abdominal fluid; BM, bone marrow; MM, mediastinal mass; SP, spleen; AH, aqueous humour; TM, thyroid mass.
DF, female; FN, female neutered; M, male; MN, male neutered. Information on neutering status was not available for Portuguese samples.
dDiagnoses comprised reactive/inflammatory (n54), and histiocytic tumour, thymoma and thyroid neoplasia (n51 each).
§All reactive/inflammatory.
Table 3. Primer sequences
Primer Sequence (5§A3§)* ReferenceD
Canine c-actin 59 6-FAM-ACCACTGGTATTGTCATGGACTCTG Gentilini et al. (2009)
Canine c-actin 272 bp 39 GCTCTTCTCCAGGGAGGACGA Gentilini et al. (2009)
Canine c-actin 720 bp 39 TGGCTTTTAGCTCACGGCACC
POL1A (59 outer) HEX-GACTTTCCAAGTTTCTAYCCNAGYATHAT Gallagher et al. (2002)
POL1B (59 outer) HEX-GACTTTCCAAGTTTCTAYCCNTCNATHAT Gallagher et al. (2002)
POL2B (39 outer and inner) 6-FAM-TTGATTAAGACGGAGTCNGTRTCNCCRTA Jarrett et al. (2013)
POL3A (59 inner) HEX-GTTTGATGCCGACCTTAYGGNTTYACNGG Gallagher et al. (2002)
POL3B (59 inner) HEX-GTTTGATGCCGACCTTAYGGNGTNACNGG Gallagher et al. (2002)
2760s (gB 59) HEX-AAGATCAACCCCACNAGNGTNATG Ehlers et al. (2008)
2761as (gB 39) 6-FAM-GTGTAGTAGTTGTACTCCCTRAACATNGTYTC Ehlers et al. (2008)
Huang 59 GGGGTGGCCAACGGCCTCTTT Huang et al. (2012)
Huang 39 TMMTYCGTAGCTGACTCGGGTGA Huang et al. (2012)
BamHI W 59 CCCCTGGTATAAAGTGGTCCTG Gallagher et al. (2003)
BamHI W probe 6-FAM-AGCTATTTCTGGTCGCATCAGAGCGC-TAMRA Gallagher et al. (2003)
BamHI W 39 CCCTCTTACATTTGTGTGGACTCC Gallagher et al. (2003)
*Dye labels are shown where appropriate. Clamp sequences in POL primers are shown in italics. Degenerate bases: Y5C or T; N5A, C, G or T;
H5A, C or T; R5A or G; M5A or C.
DReferences indicate source of previously described primers.
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(39 primers), were synthesized by Integrated DNA Technologies and
used at a final concentration of 4 mM. In semi-nested reactions, 1 ml
first-round product was used as the template. Thermal cycling was
performed on a GeneAmp PCR System 9700 (Applied Biosystems);
cycling conditions for the first round were: 95 uC for 5 min, followed
by 5 cycles of 94 uC for 60 s, 37 uC for 2 min, 72 uC for 3 min,
followed by 35 cycles of 94 uC for 60 s, 55 uC for 2 min, 72 uC for
3 min, with a final extension at 72 uC for 7 min. For second-round
reactions, and the gammaherpesvirus POL and gB assays, reaction
conditions were identical except that a 44 uC annealing temperature
was used for the first five cycles.
Sensitivity of the assays was determined by testing dilutions of DNA
from: the EBV-positive Namalwa cell line, an individual with
inherited chromosomally integrated HHV-6B (iciHHV-6B), a culture
of a HCMV clinical isolate (a kind gift from Gavin Wilkie) and the
HHV-8-positive BCP1 cell line. Droplet digital PCR was used to
accurately determine the number of viral genomes in these samples.
The droplet digital assay for HHV-6B has been published (Bell et al.,
2014), and previously described assays for EBV, HCMV and HHV-8
(Gallagher et al., 2002) were adapted for droplet digital PCR.
Replicates of dilutions containing 50 000, 5000 and 500 genomes of
HHV-6B or HCMV and 25 000, 2500 and 250 genomes of EBV were
assayed using the POL assay, and 15 000, 1500 and 150 genomes of
HHV-8 using the gB assay. DNA from the Namalwa cell line (250
copies) and iciHHV-6B individual (5000 copies) were included in all
POL assays as well as plasmids containing the polymerase gene
sequence of HHV-6B and HCMV (50 000 copies). For the gB assay,
DNA from the BCP1 cell line (150 copies) was used as the positive
control. Water was included as a negative control after every two
samples. Amplifiability of all samples was assessed using a canine c-
actin PCR amplifying a fragment of 272 bp (Table 3) (Gentilini et al.,
2009) with 100 ng DNA per reaction. Cycling conditions were: 95 uC
for 5 min, followed by 40 cycles of 95 uC for 30 s, 58 uC for 30 s,
72 uC for 30 s, with a final extension at 72 uC for 30 min.
Amplifiability of the 40 samples analysed using the gammaherpesvirus
POL and gB assays was assessed as described above using an
alternative 39 primer (Table 3) to amplify a 720 bp fragment.
PCR products were purified to remove excess primer and analysed on a
Prism 3130xl Genetic Analyzer (Applied Biosystems). Results were
examined using PeakScanner software version 1.0 (Applied Biosystems).
Samples generating amplicons in the anticipated size range for
herpesviruses, which were dual-labelled with HEX and 6-FAM, were
reamplified using unlabelled primers. Products were cloned and
sequenced using standard techniques and subjected to BLAST and BLAT
searches.
Gammaherpesvirus-specific PCR. A subset of 20 B-cell lymphoma
samples was assayed using primers described by Huang et al. (2012)
that were reported to amplify a novel canine gammaherpesvirus
sequence (Table 3). Reactions contained 16 HotStarTaq Plus Master
Mix (Qiagen) and 250 ng tumour DNA as template. The assay was
also performed using 2 ml first-round product from the degenerate
POL assay (POL1A, POL2B) as template. Namalwa DNA (2500
copies) was used as a positive control. Thermal cycling conditions
were: 95 uC for 5 min followed by 42 cycles of 94 uC for 20 s, 60 uC
for 20 s, 72 uC for 45 s and a final extension at 72 uC for 10 min in a
GeneAmp PCR System 9700 (Applied Biosystems). Reaction products
were analysed by 8% PAGE. A single fragment of appropriate size was
cloned and sequenced using standard techniques.
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